SightfileU.S. market data from official filings

Companies › AMRX

AMNEAL PHARMACEUTICALS INC (AMRX)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001723128 · EDGAR filings · Updated 2026-06-29

AMNEAL PHARMACEUTICALS INC (AMRX) has reported institutional ownership of 50.1%, with 315 institutional managers holding positions valued at $1.99B per the latest 13F reporting period. SEC filings include an active bankruptcy or receivership filing (8-K Item 1.03), non-reliance notice on previously issued financial statements (8-K Item 4.02), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04).

Institutional ownership
50.1%
Institutional managers
315
Reported 13F value
$1.99B
Insider activity
84 trans.
−$15.2M net selling
Data flags
4 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, AMNEAL PHARMACEUTICALS INC has 315 institutional holders and institutional ownership of 50.1%.

Insider activity

Insiders reported 84 transactions (0 buys, 20 sells) across 15 reporting insiders, with a net reported value of −$15.2M.

Data flags from SEC filings

Active bankruptcy or receivership filing (8-K Item 1.03), most recently filed 2025-08-01 (recurring since 2025-08-01) — source filing. The authoritative details are those stated in the filing itself.
Active non-reliance notice on previously issued financial statements (8-K Item 4.02), most recently filed 2025-08-01 (recurring since 2025-08-01) — source filing. The authoritative details are those stated in the filing itself.
Active triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04), most recently filed 2025-08-01 (recurring since 2025-08-01) — source filing. The authoritative details are those stated in the filing itself.
Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2023-12-15 (recurring since 2023-12-15) — source filing. The authoritative details are those stated in the filing itself.

Related companies

ADAPTIVE BIOTECHNOLOGIES COR (ADPT) · ULTRAGENYX PHARMACEUTICAL IN (RARE) · GENEDX HOLDINGS CORP COM CL A (WGS) · NEKTAR THERAPEUTICS (NKTR) · ADMA BIOLOGICS (ADMA) · SURGERY PARTNERS INC (SGRY)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-29.